Zydus Pharmaceuticals USA Inc. received FDA approval for its generic Gabapentin offering under ANDA #203934, positioning the company to capture market share amid the drug’s prevalence in pain management and seizure treatment. The launch of this oral formulation is expected to intensify competition within the generic neurologic drug market.